Industry View · Healthcare & Hospitals

Healthcare stopped being AI's laggard and became its fastest adopter

Healthcare AI spend nearly tripled to $1.4 billion in 2025, with providers absorbing 75% of it, while the FDA's cumulative tally of authorized AI-enabled devices hit 1,451. The money is flowing to production, not pilots — and to the administrative seams of medicine before its clinical core.

Demonstrated ROIROI Classification

Optum prior-auth cuts 45% of manual touches; ambient scribes ~45% less charting

Key Figures

$25.9B

AI-in-healthcare market, 2025

MarketsandMarkets

$1.4B

Healthcare AI spend, 2025 (~3x YoY)

Menlo Ventures

1,451

FDA AI-enabled devices authorized

FDA / Imaging Wire

81%

Physicians using AI in practice, 2026

Dialog Health / AMA

Value Chain

Drug discovery

AI-first design engines attract sovereign-scale capital

AlphaFold's commercial spinout Isomorphic Labs raised $600M (March 2025) then a $2.1B Series B, betting AI can compress preclinical timelines.

Isomorphic Labs, Recursion, Insilico

Diagnostics

Imaging is where AI is already production-grade

Radiology accounts for ~75% of 2025's 295 new FDA AI clearances; AI triage for stroke and cancer is now standard procurement.

GE HealthCare, Aidoc, Viz.ai, Tempus

Clinical decision

Point-of-care AI search goes mainstream among physicians

OpenEvidence reports use by 40%+ of US physicians, processing a month of 2024 volume in a single day — but as assistive copilot, not decision-maker.

OpenEvidence, UpToDate, Glass Health

Documentation

Ambient scribes are the fastest-adopted tech in healthcare history

The scribe category hit $600M revenue in 2025; physicians spend ~1 hour documenting per 5 hours of care, and tools cut that >50%.

Abridge, Ambience, Microsoft DAX

Payer / RCM

Automation meets regulatory and reputational friction

Optum's AI prior-auth eliminates 45% of manual touches at 96% first-pass approval, but utilization-review AI faces scrutiny over denials.

Optum, Cohere Health, Availity

01 · The thesis

The administrative wedge comes first; the clinical core follows slowly

The decisive fact of 2025 is that healthcare, long mocked as a digital laggard, now adopts AI 2.2x faster than the broader economy, with 22% of organizations running domain-specific tools versus 9% economy-wide (Menlo Ventures, survey of 700+ executives). But the spend is concentrated where ROI is unambiguous and patient risk is low: ambient documentation ($600M, +2.4x YoY) and coding-and-billing automation ($450M). Hospitals, squeezed by thin margins and staffing shortages, are the buyers; payers, wary of compliance exposure, lag with just 5% of spend and lengthening buying cycles. The clinical frontier moves on a different clock. Radiology dominates the FDA's authorizations — 1,104 of 1,451 devices, 76% of the total — because images are structured and triage is bounded. Yet the heaviest concentration of capital and hype, from OpenEvidence's $12B valuation to Abridge's $5.3B, sits in workflow and decision-support, not autonomous diagnosis. The gap between adoption breadth (most hospitals run AI somewhere) and clinical depth (under 20% embed it in core diagnosis) is the central tension of the cycle.

AI-first design engines attract sovereign-scale capital

AlphaFold's commercial spinout Isomorphic Labs raised $600M (March 2025) then a $2.1B Series B, betting AI can compress preclinical timelines.

Imaging is where AI is already production-grade

Radiology accounts for ~75% of 2025's 295 new FDA AI clearances; AI triage for stroke and cancer is now standard procurement.

Point-of-care AI search goes mainstream among physicians

OpenEvidence reports use by 40%+ of US physicians, processing a month of 2024 volume in a single day — but as assistive copilot, not decision-maker.

Ambient scribes are the fastest-adopted tech in healthcare history

The scribe category hit $600M revenue in 2025; physicians spend ~1 hour documenting per 5 hours of care, and tools cut that >50%.

Automation meets regulatory and reputational friction

Optum's AI prior-auth eliminates 45% of manual touches at 96% first-pass approval, but utilization-review AI faces scrutiny over denials.

02 · The two clocks

Three timing dynamics that govern which bets pay off

Adoption velocity has inverted the old story. Health-system AI buying cycles compressed from 8.0 to 6.6 months and outpatient from 6.0 to 4.7 months, while payer cycles lengthened to 11.3 months as insurers weigh compliance risk (Menlo Ventures, 2025). Capital follows the fast buyers: providers command 75% of the $1.4B spend. Regulatory throughput is accelerating but uneven. The FDA cleared a record 295 AI/ML devices in 2025 (up from 253 in 2024), with a 142-day median clearance time, yet 76% remain radiology — a sign clinical AI still wins approval mostly where outputs are visual and bounded (Innolitics / FDA, 2025). Valuations are running ahead of revenue. The ambient-scribe category has drawn over $4.8B in funding since 2019 against ~$600M of 2025 revenue, and OpenEvidence reached $12B in under a year — a velocity that prices in a future of agentic clinical workflows that has not yet arrived (PitchBook / CNBC).

03 · Public players & exposure

Who routes through, who gets routed around

We plot the listed players on two editorial axes — how exposed each is to AI disruption, against how ready its data, brand and position are to be the answer. The figures in the table are sourced; the placement is our read.

04 · Private flagships

The AI-native challengers

The companies attacking this industry AI-first, with disclosed funding where available:

OpenEvidence

'ChatGPT for doctors' trained only on peer-reviewed literature (NEJM, JAMA), used by 40%+ of US physicians at the point of care.

Abridge

Captures clinician-patient conversations into structured, billable Epic notes; back-to-back Best in KLAS for Ambient AI.

Ambience Healthcare

Runs scribing, real-time coding and documentation integrity from one ambient recording across 40+ health systems.

Tempus AI

AI-enabled genomic testing plus a data-licensing business; building a multimodal oncology foundation model with AstraZeneca.

Viz.ai

AI detection-and-coordination suites for stroke, vascular, cardiac and pulmonary care, alerting specialists in real time.

Isomorphic Labs

DeepMind spinout applying AlphaFold-lineage models to drug design across multiple therapeutic areas, pre-clinic.

05 · Signals

What moved, and what to watch

06 · The exposure read

Who’s defensible, who’s at risk

AI rewards clean, structured advantage and punishes friction. The line runs through who owns the data, the brand and the customer — and who is merely a step the technology can route around.

Sources

Where this comes from

The spend, and the payoff

Where 2025 healthcare AI dollars actually flow

Healthcare AI spend by buyer and category, 2025 (Menlo Ventures, 2025: The State of AI in Healthcare) ($M)

Who's defensible, who's at risk

UnitedHealth (Optum) (UNH): UnitedHealth disclosed 1,000+ AI use cases including claims, and AI now routes 26M consumer calls annually; Optum's AI prior-auth cuts 45% of manual touches (WSJ, May 2025; Optum, Feb 2026).
Tempus AI (TEM): Full-year 2025 revenue of ~$1.27B, up ~83% YoY, with diagnostics up ~111% and data licensing up ~38%; first positive adjusted EBITDA in Q3 2025 (Tempus, Feb 2026).
GE HealthCare (GEHC): Topped the FDA's AI-enabled device authorization list four years running, holding the most radiology AI authorizations at 120 including acquisitions (Imaging Wire, March 2026).
Microsoft (Dragon/DAX) (MSFT): 400+ healthcare organizations use DAX/Dragon Copilot, saving clinicians 5+ minutes per encounter; built on the $19.7B Nuance acquisition (Becker's / Microsoft, 2025).
HCA Healthcare (HCA): Deploying AI for nurse staffing, sepsis-style patient-safety monitoring and ambient ED documentation across its ~50,000-bed network (AHA, Oct 2025).
OpenEvidence (pvt): Reached a $12B valuation in January 2026, more than tripling inside a year, and used by 40%+ of US physicians; raised ~$700M from GV, Nvidia, Sequoia, Mayo Clinic (CNBC, Jan 2026).
Abridge (pvt): Raised a $300M Series E in June 2025 at a $5.3B valuation, roughly doubling in four months; Best in KLAS for Ambient AI 2025 and 2026 (TechCrunch / KLAS).
Ambience Healthcare (pvt): $243M Series C in July 2025 at a $1.25B valuation; used by 40+ health systems and reports ~45% less charting time across deployments (STAT, July 2025).
Isomorphic Labs (pvt): Raised $600M in its first external round (March 2025) then a $2.1B Series B led by Thrive, with no approved drug yet — a long-horizon bet (Isomorphic Labs / BioSpace).
Oracle (Cerner Health) (ORCL): Pushing its Clinical AI Agent across the Oracle Health EHR base, but defending share against Epic-aligned AI partners and ambient-scribe disruptors (Oracle Health, 2025).

Defensible vs At Risk

Defensible

Ambient-documentation specialists — Abridge, Ambience and Microsoft's DAX own the fastest-adopted, clearest-ROI use case, with scribe revenue at $600M and rising 2.4x YoY.
Diagnostic incumbents with data moats — GE HealthCare's four-year FDA authorization lead and Tempus's compounding data-licensing flywheel turn installed base into durable advantage.
Vertical clinical-AI platforms — OpenEvidence's physician reach shows that purpose-built, journal-trained tools beat general models in high-stakes medicine, attracting outsized capital.
Cash-strapped hospitals — providers capturing administrative-cost and staffing relief are the genuine economic beneficiaries, which is why they command 75% of spend.

At Risk

EHR incumbents slow to embed AI — Oracle Health and others risk disintermediation as ambient scribes and decision-support tools colonize the clinician workflow layer above the record.
Payers and utilization-review AI — insurers face lengthening buying cycles plus regulatory and reputational scrutiny over AI-driven denials, capping their share at ~5% of spend.
Over-funded scribe challengers — with dozens of competitors and $4.8B chasing a ~$600M revenue pool, seat pricing is under heavy downward pressure; consolidation will strand sub-scale players.
Pre-revenue AI-drug-design bets — Isomorphic-style platforms carry billion-dollar valuations on multi-year, binary clinical timelines with no approved product yet.

The signals — how it unfolded

Jan 2026

OpenEvidence doubles to $12B valuation

A Series D led by Thrive and DST cements it as the most valuable healthcare AI company, signaling investor conviction in vertical clinical AI (CNBC).

Feb 2026

Optum unveils AI-powered prior authorization

Humata-powered Digital Auth Complete claims 96% first-pass approval and 80% efficiency gains, pushing payer automation toward real-time decisions (Optum).

Feb 2026

Tempus posts ~$1.27B in 2025 revenue

AI-diagnostics revenue up ~111% and a first positive adjusted EBITDA quarter validate that diagnostic AI can carry a public-market P&L (Tempus).

2025

FDA clears a record 295 AI/ML devices

Up from 253 in 2024 across 221 manufacturers, with radiology at 76% — the regulatory pipeline is widening but still imaging-skewed (Innolitics/FDA).

Oct 2025

GE HealthCare + HCA launch CareIntellect for Perinatal

A cloud AI platform for fetal and maternal monitoring shows incumbents and providers co-developing clinical AI, not just buying scribes (AHA).

Challengers to watch